Abstract
The 2x3 cross-over design is proposed for the bioequivalence of two test drug formulations with a reference drug formulation. Oh et al.(1999) and Park et al.(1998) derived 3x2 cross-over design and discussed its benefits, since the 3x3 cross-over design may not be of practical design. We discuss the statistical issues for2x3 cross-over design and show its statistical properties. Bioequivalence problem in 2x3 cross-over design is considered statistically and an illustrated example is given.